Over the last years, the therapeutic potential of pharmaceuticals targeted at chromatin modifying enzymes, such as histone deacetylase (HDAC) inhibitors, in treatment of cognitive and behavioral impairments as well as psychiatric disorders such as anxiety, depression, fear, and schizophrenia has been repeatedly demonstrated [144–146]. Here, HDAC9 is linked to major depressive disorder.